Skip to main content
OpenTrials

Clinical trial condition

Recurrent Follicular Lymphoma

Explore clinical trials studying Recurrent Follicular Lymphoma. Study availability and eligibility vary by location and protocol.

31 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Follicular Lymphoma trial results

Completed

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

NCT02869633

Conditions
Blastoid Variant Mantle Cell Lymphoma, Chronic Disease, Disease Attributes, +27 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Stanford Cancer Institute Palo Alto, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States
View Trial Details
Completed

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

NCT01381692

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +38 more
Locations
  • Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
View Trial Details
Completed

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

NCT00723099

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, +63 more
Locations
  • University of Colorado Hospital Aurora, Colorado, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • LDS Hospital Salt Lake City, Utah, United States
  • VA Puget Sound Health Care System Seattle, Washington, United States
View Trial Details
Completed

Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

NCT01076543

Conditions
AIDS-Related Hodgkin Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +27 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Decatur Memorial Hospital Decatur, Illinois, United States
  • Ingalls Memorial Hospital Harvey, Illinois, United States
View Trial Details
Active, Not Recruiting

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

NCT03269669

Conditions
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, +12 more
Locations
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Anchorage Oncology Centre Anchorage, Alaska, United States
View all 429 locations
View Trial Details
Active, Not Recruiting

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

NCT03598998

Conditions
Anaplastic Large Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hemic and Lymphatic Diseases, +35 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Nebraska Medical Center Omaha, Nebraska, United States
View Trial Details

Related conditions